Table 3 Trends in the prescription of antibacterial compounds and for the main resistance phenotypes
From: Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis
Gradient per quarter | Gradient (95% CI) | R 2 | p value | Trend | |
|---|---|---|---|---|---|
Penicilins* | 14.61 | (0.85; 28.26) | 0.529 | 0.041 | ↑ |
Piperacillin + tazobactam* | 10.91 | (3.74; 18.08) | 0.698 | 0.010 | ↑ |
Ampicillin + enzyme inhibitor | 3.27 | (− 11.14; 17.67) | 0.049 | 0.599 | ↔ |
Amoxicillin + enzyme inhibitor | 0.34 | (− 1.72; 2.39) | 0.026 | 0.702 | ↔ |
Cephalosporins | − 15.95 | (− 34.73; 2.82) | 0.419 | 0.083 | ↔ |
Ceftriaxone* | − 28.23 | (− 47.55; − 8.91) | 0.681 | 0.012 | ↓ |
Cefuroxime | 3.48 | (− 5.60; 12.56) | 0.128 | 0.385 | ↔ |
Carbapenems* | 13.12 | (0.48; 25.75) | 0.518 | 0.044 | ↑ |
Imipenem + enzyme inhibitor | 1.55 | (− 4.57; 7.68) | 0.060 | 0.558 | ↔ |
Meropenem* | 14.63 | (6.25; 23.00) | 0.753 | 0.005 | ↑ |
Ertapenem | − 3.06 | (− 8.76; 2.63) | 0.224 | 0.237 | ↔ |
Fluoroquinolones | − 0.60 | (− 7.81; 6.60) | 0.007 | 0.844 | ↔ |
Aminoglycosides | 1.74 | (− 1.96; 5.44) | 0.180 | 0.294 | ↔ |
Other* | 27.90 | (10.37; 45.44) | 0.717 | 0.008 | ↑ |
MRSA | 0.10 | (− 0.96; 1.16) | 0.009 | 0.824 | ↔ |
ESBL E. coli | 0.12 | (− 0.08; 0.33) | 0.261 | 0.196 | ↔ |
ESBL K. pneumoniae | − 0.08 | (− 1.05; 0.90) | 0.006 | 0.850 | ↔ |
ESBL P. mirabilis | − 0.15 | (− 0.66; 0.37) | 0.074 | 0.515 | ↔ |
Combined-resistant P. aeruginosa* | 0.78 | (0.27; 1.28) | 0.707 | 0.009 | ↑ |
Carbapenem-resistant Ps. aeruginosa* | 0.74 | (0.21; 1.27) | 0.666 | 0.013 | ↑ |
Carbapenem-resistant A. baumannii | − 0.10 | (− 0.59; 3.99) | 0.039 | 0.641 | ↔ |